Fagron SA FAGR

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 29 September 2026 – 6 PM CET Disclosure of a transparency notification from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from BlackRock, Inc., dated 24 September 2026. Notification from BlackRock, Inc. On 25 September 2026, Fagron received a transparency notification from BlackRock, Inc. informing the Company

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 21 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 43,920 new shares have been issued on 21 September 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,764,714.08. The total number of shares with voting rights after the issue amounts

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 July 2026 – 7:00 AM CET Fagron delivers strong H1 2026 performance with 16% topline growth and reiterates FY 2026 guidance Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2026. Key Highlights Revenue up 16.0% to €552.5 million (17.5% at CER), with organic growth of 3.1% at CER, led by EMEA and Latin America and supported by contributions fr

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 3 June 2026 – 6 PM CET Disclosure of transparency notification from FMR LLC Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from FMR LLC, dated 29 May 2026. According to the notification, the shareholding reported by FMR LLC arises from holdings of various undertakings for collective investment managed by FIAM LLC, Fidelity Inst

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 18 May 2026 – 6 PM CET Disclosure of transparency notifications from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received two transparency notifications from BlackRock, Inc., dated 13 May 2026. Notifications from BlackRock, Inc. On 13 and 14 May 2026, Fagron received two transparency notifications from BlackRock, Inc.: In the first notification,

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 May 2026 – 6PM CET Fagron shareholders approve all proposed resolutions at the General Meetings Fagron, the leading global player in pharmaceutical compounding, today held its Annual and Extraordinary General Meeting of Shareholders. All resolutions proposed by the Board of Directors were approved. Resolutions approved at the General Meetings The Annual General Meeting approved the annual accounts and the other annual docume

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 April 2026 – 6 PM CET Disclosure of transparency notification from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from BlackRock, Inc., dated 28 April 2026. Notification from BlackRock, Inc. On 28 April 2026, Fagron received a transparency notification from BlackRock, Inc., informing the Company that its shar

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2026 – 7 AM CEST Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 Fagron NV invites its shareholders and holders of subscription rights to attend its Ordinary General Meeting and Extraordinary General Meeting, to be held on Monday, 11 May 2026, starting at 15:00 CEST. The Extraordinary General Meeting will be held before notary and will take place immediately following the Ordinary General Meet

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2026. Key Highlights Revenue of €263.4 million, up 10.3% on a reported basis (15.0% at CER1), supported by incremental M&A contribution and outstanding performance in Latin America

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 104,200 new shares have been issued on 31 March 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,462,601.84. The total number of shares with voting rights after the issue amounts to

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 20 March 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from Aberdeen Group plc, dated 16 March 2026. Notification from Aberdeen Group plc On 19 March 2026, Fagron received a transparency notification from Aberdeen Group plc, informing the Company